Trabodenoson 在小鼠干眼症模型中的疗效
本研究在成年雄性 C57BL/6 小鼠中,用干燥环境联合经皮给予东莨菪碱诱导干眼症,并比较溶媒、6% trabodenoson 与 0.05% 环孢素(Restasis)每日两次治疗的效果。结果显示,trabodenoson 可升高泪液量、减少角膜荧光素染色,并减轻泪腺免疫细胞浸润、增加结膜杯状细胞,这些效果与环孢素相似或更优,提示其可能通过腺苷信号通路发挥抗炎作用。
要点
- trabodenoson 每日两次点眼可增加干眼小鼠泪液并减少角膜荧光素染色(P < 0.05)。
- trabodenoson 减轻泪腺免疫细胞浸润并增加结膜杯状细胞(均 P < 0.05)。
- 其对泪腺病理与杯状细胞的作用与环孢素相似或更优,或为干眼新疗法。
核心结论
- 局部点眼给予 trabodenoson 可显著改善小鼠干眼症相关的临床与组织病理学表现。
- 该改善可能与靶向腺苷信号通路的抗炎作用有关,是干眼治疗的新方向。
研究设计与样本
- 在成年雄性 C57BL/6 小鼠中,用干燥环境联合经皮给予东莨菪碱诱导干眼症。
- 小鼠同期每日两次接受溶媒、6% trabodenoson 或 0.05% 环孢素(Restasis)治疗。
- 疗效通过角膜荧光素染色、泪液量及泪腺病理与结膜杯状细胞定量评估(与溶媒比较 P < 0.05 为有效)。
主要发现
- 与溶媒治疗眼相比,trabodenoson 每日两次点眼增加泪液水平并减少角膜荧光素染色(P < 0.05)。
- 未治疗与溶媒治疗眼均可见泪腺显著免疫细胞浸润及产黏蛋白结膜杯状细胞减少。
- trabodenoson 显著减少泪腺浸润并增加杯状细胞数量(两项与溶媒比较均 P < 0.05)。
- trabodenoson 对泪腺病理与杯状细胞的作用与环孢素治疗相似或更优。
关键数值与推荐
- trabodenoson 浓度 6%,环孢素(Restasis)浓度 0.05%,均每日两次给药。
- 疗效判定阈值:与溶媒比较 P < 0.05。
- 泪液量增加、角膜荧光素染色减少、泪腺浸润减少与杯状细胞增加均达 P < 0.05。
临床怎么用
- 提示 trabodenoson 点眼可能同时改善干眼症状体征与泪腺、结膜的组织病理改变。
- 其抗炎机制与环孢素相似或更优,支持进一步开发为干眼治疗药物。
- 目前仅为小鼠临床前证据,尚不能直接外推至人类干眼患者的用药方案。
局限性
- 证据来自小鼠干眼模型,属于临床前研究,尚未在人体验证。
- 原文未报告样本量、具体效应值及置信区间。
- 诱导模型为干燥环境联合东莨菪碱,与人类干眼异质性可能存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the efficacy of trabodenoson, an adenosine mimetic with highly selective adenosine A1 receptor binding properties, in a preclinical mouse model for dry-eye disease. METHODS: Dry-eye disease was induced in adult male C57BL/6 mice using a combination of desiccating environment and transdermal administration of scopolamine. Mice were treated concurrently and twice daily with either vehicle, 6% trabodenoson, or 0.05% cyclosporine (Restasis). Efficacy (P < 0.05 versus vehicle) was determined by clinical assessment of dry-eye symptoms using corneal fluorescein staining and tear volumes and histopathologically by quantifying lacrimal gland pathology and conjunctival goblet cells. RESULTS: Twice-daily topical (ocular) administration of trabodenoson increased tear levels and reduced corneal fluorescein staining (P < 0.05) as compared with vehicle-treated eyes in a mouse model of dry-eye disease. Furthermore, significant infiltration of immune cells in the lacrimal gland and reduced number of mucin-producing conjunctival goblet cells were noted in both untreated and vehicle-treated eyes. Comparatively, trabodenoson treatment significantly reduced lacrimal gland infiltration and increased the number of goblet cells (P < 0.05 for both versus vehicle). These trabodenoson-related effects on lacrimal gland pathology and goblet cells were similar to or better than the effects observed with cyclosporine treatment. CONCLUSIONS: Topical ocular delivery of trabodenoson significantly improves the clinical and histopathological signs associated with dry-eye disease in mice. This improvement appears to be related to anti-inflammatory effects from targeting adenosine signaling and represents a novel therapeutic approach to develop for the management of dry-eye disease.
引用
- Žiniauskaite A, Ragauskas S, Hakkarainen JJ, et al. Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome. Invest Ophthalmol Vis Sci. 2018. PMID: 30025146. doi:10.1167/iovs.18-24432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。